Neuroprotective strategies after neonatal hypoxic ischemic encephalopathy

International Journal of Molecular Sciences

Volumn 16, Issue 9, 2015, Pages 22368-22401

  Dixon, Brandon J ^a   Reis, Cesar ^a,b   Ho, Wing Mann ^a,c   Tang, Jiping ^a   Zhang, John H ^a,b  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Intervention strategy; Neonatal hypoxic ischemic encephalopathy; Neuroprotection

Indexed keywords

BETA INTERFERON; MELATONIN; OSTEOPONTIN; TOPIRAMATE; XENON; NEUROPROTECTIVE AGENT;

CENTRAL NERVOUS SYSTEM FUNCTION; CLINICAL FEATURE; DISEASE COURSE; HUMAN; HYPOXIC ISCHEMIC ENCEPHALOPATHY; MORBIDITY; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TREATMENT PLANNING; CLINICAL TRIAL (TOPIC); HYPOXIA-ISCHEMIA, BRAIN; NEWBORN;

CLINICAL TRIALS AS TOPIC; HUMANS; HYPOXIA-ISCHEMIA, BRAIN; INFANT, NEWBORN; NEUROPROTECTIVE AGENTS; STEM CELL TRANSPLANTATION;

EID: 84941695616     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160922368     Document Type: Review

References (220)

1. Shetty, J. Neonatal seizures in hypoxic-ischaemic encephalopathy-risks and benefits of anticonvulsant therapy. Dev. Med. Child. Neurol. 2015, 57, 40-43.
2. Volpe, J.J. Perinatal brain injury: From pathogenesis to neuroprotection. Ment. Retard. Dev. Disabil. Res. Rev. 2001, 7, 56-64.
3. Doycheva, D.; Shih, G.; Chen, H.; Applegate, R.; Zhang, J.H.; Tang, J. Granulocyte-colony stimulating factor in combination with stem cell factor confers greater neuroprotection after hypoxic-ischemic brain damage in the neonatal rats than a solitary treatment. Transl. Stroke Res. 2013, 4, 171-178.
4. Northington, F.J.; Chavez-Valdez, R.; Martin, L.J. Neuronal cell death in neonatal hypoxia-ischemia. Ann. Neurol. 2011, 69, 743-758.
5. Gill, M.B.; Perez-Polo, J.R. Hypoxia ischemia-mediated cell death in neonatal rat brain. Neurochem. Res. 2008, 33, 2379-2389.
6. Badr Zahr, L.K.; Purdy, I. Brain injury in the infant: The old, the new, and the uncertain. J. Perinat. Neonatal Nurs. 2006, 20, 163-175.
7. Shankaran, S. Hypoxic-ischemic encephalopathy and novel strategies for neuroprotection. Clin. Perinat. 2012, 39, 919-929.
8. Fathali, N.; Lekic, T.; Zhang, J.H.; Tang, J. Long-term evaluation of granulocyte-colony stimulating factor on hypoxic-ischemic brain damage in infant rats. Intensive Care Med. 2010, 36, 1602-1608.
9. Wayock, C.P.; Meserole, R.L.; Saria, S.; Jennings, J.M.; Huisman, T.A.; Northington, F.J.; Graham, E.M. Perinatal risk factors for severe injury in neonates treated with whole-body hypothermia for encephalopathy. Am. J. Obstet. Gynecol. 2014, 211, 41-48.
10. Douglas-Escobar, M.; Weiss, M.D. Hypoxic-ischemic encephalopathy: A review for the clinician. JAMA Pediatr. 2015, 169, 397-403.
11. Logitharajah, P.; Rutherford, M.A.; Cowan, F.M. Hypoxic-ischemic encephalopathy in preterm infants: Antecedent factors, brain imaging, and outcome. Pediatr. Res. 2009, 66, 222-229.
12. Vasudevan, C.; Levene, M. Epidemiology and aetiology of neonatal seizures. Semin. Fetal Neonatal Med. 2013, 18, 185-191.
13. Lombroso, C.T. Neonatal seizures: Gaps between the laboratory and the clinic. Epilepsia 2007, 48, 83-106.
14. Sheth, R.D. Electroencephalogram confirmatory rate in neonatal seizures. Pediatr. Neurol. 1999, 20, 27-30.
15. Silverstein, F.S.; Jensen, F.E. Neonatal seizures. Ann. Neurol. 2007, 62, 112-120.
16. Eunson, P. The long-term health, social, and financial burden of hypoxic-ischaemic encephalopathy. Dev. Med. Child. Neurol. 2015, 57, 48-50.
17. Volpe, J.J. Neonatal encephalopathy: An inadequate term for hypoxic-ischemic encephalopathy. Ann. Neurol. 2012, 72, 156-166.
18. Robertson, C.M.; Perlman, M. Follow-up of the term infant after hypoxic-ischemic encephalopathy. Paediatr. Child. Health 2006, 11, 278-282.
19. Fathali, N.; Khatibi, N.H.; Ostrowski, R.P.; Zhang, J.H. The evolving landscape of neuroinflammation after neonatal hypoxia-ischemia. Acta Neurochir. Suppl. 2011, 111, 93-100.
20. Wachtel, E.V.; Hendricks-Munoz, K.D. Current management of the infant who presents with neonatal encephalopathy. Curr. Probl. Pediatr. Adolesc. Health Care 2011, 41, 132-153.
21. Yager, J.Y.; Ashwal, S. Animal models of perinatal hypoxic-ischemic brain damage. Pediatr. Neurol. 2009, 40, 156-167.
22. Allen, K.A.; Brandon, D.H. Hypoxic ischemic encephalopathy: Pathophysiology and experimental treatments. Newborn Infant Nurs. Rev. 2011, 11, 125-133.
23. Baburamani, A.A.; Ek, C.J.; Walker, D.W.; Castillo-Melendez, M. Vulnerability of the developing brain to hypoxic-ischemic damage: Contribution of the cerebral vasculature to injury and repair? Front. Physiol. 2012, 3, 424.
24. Ginet, V.; Puyal, J.; Clarke, P.G.; Truttmann, A.C. Enhancement of autophagic flux after neonatal cerebral hypoxia-ischemia and its region-specific relationship to apoptotic mechanisms. Am. J. Pathol. 2009, 175, 1962-1974.
25. Seevinck, P.R.; Deddens, L.H.; Dijkhuizen, R.M. Magnetic resonance imaging of brain angiogenesis after stroke. Angiogenesis 2010, 13, 101-111.
26. Johnston, M.V.; Trescher, W.H.; Ishida, A.; Nakajima, W. Neurobiology of hypoxic-ischemic injury in the developing brain. Pediatr. Res. 2001, 49, 735-741.
27. Lai, M.C.; Yang, S.N. Perinatal hypoxic-ischemic encephalopathy. J. Biomed. Biotechnol. 2011, 2011, 609813.
28. Kumar, P.; Halamek, L.P. Resuscitation of the Fetus and Newborn, an Issue of Clinics in Perinatology; Elsevier Health Sciences: Philadelphia, PA, USA, 2012.
29. Juul, S.E.; Ferriero, D.M. Pharmacologic neuroprotective strategies in neonatal brain injury. Clin. Perinatol. 2014, 41, 119-131.
30. Lorek, A.; Takei, Y.; Cady, E.B.; Wyatt, J.S.; Penrice, J.; Edwards, A.D.; Peebles, D.; Wylezinska, M.; Owen-Reece, H.; Kirkbride, V. et al. Delayed ("secondary") cerebral energy failure after acute hypoxia-ischemia in the newborn piglet: Continuous 48-hour studies by phosphorus magnetic resonance spectroscopy. Pediatr. Res. 1994, 36, 699-706.
31. Vannucci, R.C.; Towfighi, J.; Vannucci, S.J. Secondary energy failure after cerebral hypoxia-ischemia in the immature rat. J. Cereb. Blood Flow Metab. 2004, 24, 1090-1097.
32. Laptook, A. The importance of temperature on the neurovascular unit. Early Hum. Dev. 2014, 90, 713-717.
33. Ballabh, P.; Braun, A.; Nedergaard, M. The blood-brain barrier: An overview: Structure, regulation, and clinical implications. Neurobiol. Dis. 2004, 16, 1-13.
34. Kumar, A.; Mittal, R.; Khanna, H.D.; Basu, S. Free radical injury and blood-brain barrier permeability in hypoxic-ischemic encephalopathy. Pediatrics 2008, 122, 722-727.
35. Moretti, R.; Pansiot, J.; Bettati, D.; Strazielle, N.; Ghersi-Egea, J.F.; Damante, G.; Fleiss, B.; Titomanlio, L.; Gressens, P. Blood-brain barrier dysfunction in disorders of the developing brain. Front. Neurosci. 2015, 9, 40.
36. Wu, J.; Zhao, D.; Wu, S.; Wang, D. Ang-(1-7) exerts protective role in blood-brain barrier damage by the balance of timp-1/mmp-9. Eur. J. Pharmacol. 2015, 748, 30-36.
37. Zhao, T.; Zhang, X.; Zhao, Y.; Zhang, L.; Bai, X.; Zhang, J.; Zhao, X.; Chen, L.; Wang, L.; Cui, L. Pretreatment by evodiamine is neuroprotective in cerebral ischemia: Up-regulated pakt, pgsk3beta, down-regulated nf-kappab expression, and ameliorated bbb permeability. Neurochem. Res. 2014, 39, 1612-1620.
38. Hou, C.W.; Chen, Y.L.; Chuang, S.H.; Wang, J.S.; Jeng, K.C. Protective effect of a sesamin derivative, 3-bis (3-methoxybenzyl) butane-1, 4-diol on ischemic and hypoxic neuronal injury. J. Biomed. Sci. 2014, 21, 15.
39. Wang, Y.F.; Gu, Y.T.; Qin, G.H.; Zhong, L.; Meng, Y.N. Curcumin ameliorates the permeability of the blood-brain barrier during hypoxia by upregulating heme oxygenase-1 expression in brain microvascular endothelial cells. J. Mol. Neurosci. 2013, 51, 344-351.
40. Song, J.; Cheon, S.Y.; Lee, W.T.; Park, K.A.; Lee, J.E. The effect of ask1 on vascular permeability and edema formation in cerebral ischemia. Brain Res. 2015, 1595, 143-155.
41. Li, L.; McBride, D.W.; Doycheva, D.; Dixon, B.J.; Krafft, P.R.; Zhang, J.H.; Tang, J. G-csf attenuates neuroinflammation and stabilizes the blood-brain barrier via the pi3k/akt/gsk-3beta signaling pathway following neonatal hypoxia-ischemia in rats. Exp. Neurol. 2015, doi:10.1016/j.expneurol.2014.12.020.
42. Yang, D.; Nemkul, N.; Shereen, A.; Jone, A.; Dunn, R.S.; Lawrence, D.A.; Lindquist, D.; Kuan, C.Y. Therapeutic administration of plasminogen activator inhibitor-1 prevents hypoxic-ischemic brain injury in newborns. J. Neurosci. 2009, 29, 8669-8674.
43. Engelhardt, S.; Huang, S.F.; Patkar, S.; Gassmann, M.; Ogunshola, O.O. Differential responses of blood-brain barrier associated cells to hypoxia and ischemia: A comparative study. Fluids Barriers CNS 2015, 12, 4.
44. Shaikh, H.; Lechpammer, M.; Jensen, F.E.; Warfield, S.K.; Hansen, A.H.; Kosaras, B.; Shevell, M.; Wintermark, P. Increased brain perfusion persists over the first month of life in term asphyxiated newborns treated with hypothermia: Does it reflect activated angiogenesis? Transl. Stroke Res. 2015, 6, 224-233.
45. Shaikh, H.; Boudes, E.; Khoja, Z.; Shevell, M.; Wintermark, P. Angiogenesis dysregulation in term asphyxiated newborns treated with hypothermia. PLoS ONE 2015, 10, 128028.
46. Pimentel-Coelho, P.M.; Rosado-de-Castro, P.H.; da Fonseca, L.M.; Mendez-Otero, R. Umbilical cord blood mononuclear cell transplantation for neonatal hypoxic-ischemic encephalopathy. Pediatr. Res. 2012, 71, 464-473.
47. Chen, A.; Xiong, L.J.; Tong, Y.; Mao, M. The neuroprotective roles of bdnf in hypoxic ischemic brain injury. Biomed. Rep. 2013, 1, 167-176.
48. Eriksson, P.S.; Perfilieva, E.; Bjork-Eriksson, T.; Alborn, A.M.; Nordborg, C.; Peterson, D.A.; Gage, F.H. Neurogenesis in the adult human hippocampus. Nat. Med. 1998, 4, 1313-1317.
49. Guidi, S.; Bianchi, P.; Alstrup, A.K.; Henningsen, K.; Smith, D.F.; Bartesaghi, R. Postnatal neurogenesis in the hippocampal dentate gyrus and subventricular zone of the gottingen minipig. Brain Res. Bull. 2011, 85, 169-179.
50. Donega, V.; van Velthoven, C.T.; Nijboer, C.H.; Kavelaars, A.; Heijnen, C.J. The endogenous regenerative capacity of the damaged newborn brain: Boosting neurogenesis with mesenchymal stem cell treatment. J. Cereb. Blood Flow Metab. 2013, 33, 625-634.
51. Ong, J.; Plane, J.M.; Parent, J.M.; Silverstein, F.S. Hypoxic-ischemic injury stimulates subventricular zone proliferation and neurogenesis in the neonatal rat. Pediatr. Res. 2005, 58, 600-606.
52. Van Velthoven, C.T.; Kavelaars, A.; van Bel, F.; Heijnen, C.J. Mesenchymal stem cell treatment after neonatal hypoxic-ischemic brain injury improves behavioral outcome and induces neuronal and oligodendrocyte regeneration. Brain Behav. Immun. 2010, 24, 387-393.
53. Fernandez-Lopez, D.; Natarajan, N.; Ashwal, S.; Vexler, Z.S. Mechanisms of perinatal arterial ischemic stroke. J. Cereb. Blood Flow Metab. 2014, 34, 921-932.
54. Ohsumi, Y. Historical landmarks of autophagy research. Cell. Res. 2014, 24, 9-23.
55. Li, Q.; Li, H.; Roughton, K.; Wang, X.; Kroemer, G.; Blomgren, K.; Zhu, C. Lithium reduces apoptosis and autophagy after neonatal hypoxia-ischemia. Cell. Death Dis. 2010, 1, 56.
56. Balduini, W.; Carloni, S.; Buonocore, G. Autophagy in hypoxia-ischemia induced brain injury. J. Mater. Fetal Neonatal Med. 2012, 25, 30-34.
57. Chen, A.; Xiong, L.J.; Tong, Y.; Mao, M. Neuroprotective effect of brain-derived neurotrophic factor mediated by autophagy through the pi3k/akt/mtor pathway. Mol. Med. Rep. 2013, 8, 1011-1016.
58. Vannucci, S.J.; Hagberg, H. Hypoxia-ischemia in the immature brain. J. Exp. Biol. 2004, 207, 3149-3154.
59. Hartung, T.; Daston, G. Are in vitro tests suitable for regulatory use? Toxicol. Sci. 2009, 111, 233-237.
60. De Clercq, E. Recent highlights in the development of new antiviral drugs. Curr. Opin. Microbiol. 2005, 8, 552-560.
61. Perel, P.; Roberts, I.; Sena, E.; Wheble, P.; Briscoe, C.; Sandercock, P.; Macleod, M.; Mignini, L.E.; Jayaram, P.; Khan, K.S. Comparison of treatment effects between animal experiments and clinical trials: Systematic review. BMJ 2007, 334, 197.
62. Hackam, D.G.; Redelmeier, D.A. Translation of research evidence from animals to humans. JAMA 2006, 296, 1731-1732.
63. O'Collins, V.E.; Macleod, M.R.; Donnan, G.A.; Horky, L.L.; van der Worp, B.H.; Howells, D.W. 1026 experimental treatments in acute stroke. Ann. Neurol. 2006, 59, 467-477.
64. Johnston, M.V.; Ferriero, D.M.; Vannucci, S.J.; Hagberg, H. Models of cerebral palsy: Which ones are best? J. Child. Neurol. 2005, 20, 984-987.
65. Ashwal, S.; Tone, B.; Tian, H.R.; Chong, S.; Obenaus, A. Comparison of two neonatal ischemic injury models using magnetic resonance imaging. Pediatr. Res. 2007, 61, 9-14.
66. Yang, T.; Zhuang, L.; Terrando, N.; Wu, X.; Jonhson, M.R.; Maze, M.; Ma, D. A clinically relevant model of perinatal global ischemic brain damage in rats. Brain Res. 2011, 1383, 317-323.
67. Huang, Y.; Lai, H.; Xu, H.; Wu, W.; Lai, X.; Ho, G.; Ma, L.; Chen, Y. Impact of perinatal systemic hypoxic-ischemic injury on the brain of male offspring rats: An improved model of neonatal hypoxic-ischemic encephalopathy in early preterm newborns. PLoS ONE 2013, 8, 82502.
68. Tsuji, M.; Ohshima, M.; Taguchi, A.; Kasahara, Y.; Ikeda, T.; Matsuyama, T. A novel reproducible model of neonatal stroke in mice: Comparison with a hypoxia-ischemia model. Exp. Neurol. 2013, 247, 218-225.
69. Northington, F.J. Brief update on animal models of hypoxic-ischemic encephalopathy and neonatal stroke. ILAR J. 2006, 47, 32-38.
70. Clowry, G.J.; Basuodan, R.; Chan, F. What are the best animal models for testing early intervention in cerebral palsy? Front. Neurol. 2014, 5, 258.
71. Teo, L.; Bourne, J.A. A reproducible and translatable model of focal ischemia in the visual cortex of infant and adult marmoset monkeys. Brain Pathol. 2014, 24, 459-474.
72. Sena, E.; van der Worp, H.B.; Howells, D.; Macleod, M. How can we improve the pre-clinical development of drugs for stroke? Trends Neurosci. 2007, 30, 433-439.
73. Van der Worp, H.B.; Howells, D.W.; Sena, E.S.; Porritt, M.J.; Rewell, S.; O'Collins, V.; Macleod, M.R. Can animal models of disease reliably inform human studies? PLoS Med. 2010, 7, 1000245.
74. Saver, J.L.; Johnston, K.C.; Homer, D.; Wityk, R.; Koroshetz, W.; Truskowski, L.L.; Haley, E.C. Infarct volume as a surrogate or auxiliary outcome measure in ischemic stroke clinical trials. Stroke 1999, 30, 293-298.
75. The National Institute of Neurological Disorders and Stroke (Ninds) rt-pa Stroke Study Group. Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. Stroke 2000, 31, 2912-2919.
76. Van der Worp, H.B.; de Haan, P.; Morrema, E.; Kalkman, C.J. Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia. J. Neurol. 2005, 252, 1108-1114.
77. Langley, G.; Evans, T.; Holgate, S.T.; Jones, A. Replacing animal experiments: Choices, chances and challenges. BioEssays 2007, 29, 918-926.
78. Sena, E.S.; van der Worp, H.B.; Bath, P.M.; Howells, D.W.; Macleod, M.R. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol. 2010, 8, 1000344.
79. Upadhyay, R.K. Drug delivery systems, cns protection, and the blood brain barrier. Biomed. Res. Int. 2014, 2014, 869269.
80. Alavijeh, M.S.; Chishty, M.; Qaiser, M.Z.; Palmer, A.M. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. NeuroRx 2005, 2, 554-571.
81. Pardridge, W.M. The blood-brain barrier: Bottleneck in brain drug development. NeuroRx 2005, 2, 3-14.
82. Sanchez-Covarrubias, L.; Slosky, L.M.; Thompson, B.J.; Davis, T.P.; Ronaldson, P.T. Transporters at cns barrier sites: Obstacles or opportunities for drug delivery? Curr. Pharm. Des. 2014, 20, 1422-1449.
83. Ek, C.J.; D'Angelo, B.; Baburamani, A.A.; Lehner, C.; Leverin, A.L.; Smith, P.L.; Nilsson, H.; Svedin, P.; Hagberg, H.; Mallard, C. Brain barrier properties and cerebral blood flow in neonatal mice exposed to cerebral hypoxia-ischemia. J. Cereb. Blood Flow Metab. 2015, 35, 818-827.
84. Allegaert, K.; van den Anker, J.N. Clinical pharmacology in neonates: Small size, huge variability. Neonatology 2014, 105, 344-349.
85. Turner, M.A. Neonatal drug development. Early Hum. Dev. 2011, 87, 763-768.
86. Dabliz, R.; Levine, S. Medication safety in neonates. Am. J. Perinatol. 2012, 29, 49-56.
87. Du, W.; Lehr, V.T.; Lieh-Lai, M.; Koo, W.; Ward, R.M.; Rieder, M.J.; van den Anker, J.N.; Reeves, J.H.; Mathew, M.; Lulic-Botica, M. et al. An algorithm to detect adverse drug reactions in the neonatal intensive care unit. J. Clin. Pharmacol. 2013, 53, 87-95.
88. Tuleu, C. 'Formulating better medicines for children'—Still paving the road. Int. J. Pharm. 2012, 435, 99-100.
89. Van den Anker, J.; Allegaert, K. Clinical pharmacology in neonates and young infants: The benefit of a population-tailored approach. Exp. Rev. Clin. Pharmacol. 2012, 5, 5-8.
90. Choonara, I. Who wants safer medicines for children. Arch. Dis. Child. 2008, 93, 456-457.
91. Salunke, S.; Giacoia, G.; Tuleu, C. The step (safety and toxicity of excipients for paediatrics) database. Part 1—A need assessment study. Int. J. Pharm. 2012, 435, 101-111.
92. Nahata, M.C. Safety of “inert” additives or excipients in paediatric medicines. Arch. Dis. child. Fetal Neonatal Ed. 2009, 94, 392-393.
93. Turner, M.A.; Storme, T. European study for neonatal excipient exposure (esnee). Eur. J. Hosp. Pharm. 2012, 19, 67.
94. Johnston, M.V.; Fatemi, A.; Wilson, M.A.; Northington, F. Treatment advances in neonatal neuroprotection and neurointensive care. Lancet Neurol. 2011, 10, 372-382.
95. O'Regan, A.; Berman, J.S. Osteopontin: A key cytokine in cell-mediated and granulomatous inflammation. Int. J. Exp. Pathol. 2000, 81, 373-390.
96. Chabot, S.; Williams, G.; Yong, V.W. Microglial production of tnf-alpha is induced by activated T lymphocytes. Involvement of vla-4 and inhibition by interferonbeta-1b. J. Clin. Investig. 1997, 100, 604-612.
97. Dhanasekaran, D.N.; Reddy, E.P. Jnk signaling in apoptosis. Oncogene 2008, 27, 6245-6251.
98. Nijboer, C.H.; Heijnen, C.J.; Groenendaal, F.; van Bel, F.; Kavelaars, A. Alternate pathways preserve tumor necrosis factor-alpha production after nuclear factor-kappab inhibition in neonatal cerebral hypoxia-ischemia. Stroke 2009, 40, 3362-3368.
99. Nijboer, C.H.; Bonestroo, H.J.; Zijlstra, J.; Kavelaars, A.; Heijnen, C.J. Mitochondrial jnk phosphorylation as a novel therapeutic target to inhibit neuroinflammation and apoptosis after neonatal ischemic brain damage. Neurobiol. Dis. 2013, 54, 432-444.
100. Meyn, D.F., Jr.; Ness, J.; Ambalavanan, N.; Carlo, W.A. Prophylactic phenobarbital and whole-body cooling for neonatal hypoxic-ischemic encephalopathy. J. Pediatr. 2010, 157, 334-336.
101. Alonso-Alconada, D.; Alvarez, A.; Arteaga, O.; Martinez-Ibarguen, A.; Hilario, E. Neuroprotective effect of melatonin: A novel therapy against perinatal hypoxia-ischemia. Int. J. Mol. Sci. 2013, 14, 9379-9395.
102. Carloni, S.; Perrone, S.; Buonocore, G.; Longini, M.; Proietti, F.; Balduini, W. Melatonin protects from the long-term consequences of a neonatal hypoxic-ischemic brain injury in rats. J. Pineal. Res. 2008, 44, 157-164.
103. Robertson, N.J.; Faulkner, S.; Fleiss, B.; Bainbridge, A.; Andorka, C.; Price, D.; Powell, E.; Lecky-Thompson, L.; Thei, L.; Chandrasekaran, M. et al. Melatonin augments hypothermic neuroprotection in a perinatal asphyxia model. Brain 2013, 136, 90-105.
104. Aly, H.; Elmahdy, H.; El-Dib, M.; Rowisha, M.; Awny, M.; El-Gohary, T.; Elbatch, M.; Hamisa, M.; El-Mashad, A.R. Melatonin use for neuroprotection in perinatal asphyxia: A randomized controlled pilot study. J. Perinatol. 2015, 35, 186-191.
105. Takizawa, Y.; Miyazawa, T.; Nonoyama, S.; Goto, Y.; Itoh, M. Edaravone inhibits DNA peroxidation and neuronal cell death in neonatal hypoxic-ischemic encephalopathy model rat. Pediatr. Res. 2009, 65, 636-641.
106. Noor, J.I.; Ueda, Y.; Ikeda, T.; Ikenoue, T. Edaravone inhibits lipid peroxidation in neonatal hypoxic-ischemic rats: An in vivo microdialysis study. Neurosci. Lett. 2007, 414, 5-9.
107. Ni, X.; Yang, Z.J.; Carter, E.L.; Martin, L.J.; Koehler, R.C. Striatal neuroprotection from neonatal hypoxia-ischemia in piglets by antioxidant treatment with euk-134 or edaravone. Dev. Neurosci. 2011, 33, 299-311.
108. Villa, P.; Bigini, P.; Mennini, T.; Agnello, D.; Laragione, T.; Cagnotto, A.; Viviani, B.; Marinovich, M.; Cerami, A.; Coleman, T.R. et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J. Exp. Med. 2003, 198, 971-975.
109. Wang, L.; Zhang, Z.; Wang, Y.; Zhang, R.; Chopp, M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004, 35, 1732-1737.
110. Juul, S.E. Hypothermia plus erythropoietin for neonatal neuroprotection? Commentary on Fan et al. and Fang et al. Pediatr. Res. 2013, 73, 10-11.
111. Bernaudin, M.; Marti, H.H.; Roussel, S.; Divoux, D.; Nouvelot, A.; MacKenzie, E.T.; Petit, E. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J. Cereb. Blood Flow Metab. 1999, 19, 643-651.
112. Mu, D.; Chang, Y.S.; Vexler, Z.S.; Ferriero, D.M. Hypoxia-inducible factor 1alpha and erythropoietin upregulation with deferoxamine salvage after neonatal stroke. Exp. Neurol. 2005, 195, 407-415.
113. Palmer, C.; Towfighi, J.; Roberts, R.L.; Heitjan, D.F. Allopurinol administered after inducing hypoxia-ischemia reduces brain injury in 7-day-old rats. Pediatr. Res. 1993, 33, 405-411.
114. Kaandorp, J.J.; Benders, M.J.; Schuit, E.; Rademaker, C.M.; Oudijk, M.A.; Porath, M.M.; Oetomo, S.B.; Wouters, M.G.; van Elburg, R.M.; Franssen, M.T. et al. Maternal allopurinol administration during suspected fetal hypoxia: A novel neuroprotective intervention? A multicentre randomised placebo controlled trial. Arch. Dis. Child. Fetal Neonatal Ed. 2015, 100, 216-223.
115. David, H.N.; Haelewyn, B.; Rouillon, C.; Lecoq, M.; Chazalviel, L.; Apiou, G.; Risso, J.J.; Lemaire, M.; Abraini, J.H. Neuroprotective effects of xenon: A therapeutic window of opportunity in rats subjected to transient cerebral ischemia. FASEB J. 2008, 22, 1275-1286.
116. Ma, D.; Hossain, M.; Chow, A.; Arshad, M.; Battson, R.M.; Sanders, R.D.; Mehmet, H.; Edwards, A.D.; Franks, N.P.; Maze, M. Xenon and hypothermia combine to provide neuroprotection from neonatal asphyxia. Ann. Neurol. 2005, 58, 182-193.
117. Follett, P.L.; Deng, W.; Dai, W.; Talos, D.M.; Massillon, L.J.; Rosenberg, P.A.; Volpe, J.J.; Jensen, F.E. Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: A protective role for topiramate. J. Neurosci. 2004, 24, 4412-4420.
118. Kaminski, R.M.; Banerjee, M.; Rogawski, M.A. Topiramate selectively protects against seizures induced by atpa, a glur5 kainate receptor agonist. Neuropharmacology 2004, 46, 1097-1104.
119. Koh, S.; Tibayan, F.D.; Simpson, J.N.; Jensen, F.E. Nbqx or topiramate treatment after perinatal hypoxia-induced seizures prevents later increases in seizure-induced neuronal injury. Epilepsia 2004, 45, 569-575.
120. Zona, C.; Ciotti, M.T.; Avoli, M. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci. Lett. 1997, 231, 123-126.
121. Costa, C.; Martella, G.; Picconi, B.; Prosperetti, C.; Pisani, A.; di Filippo, M.; Pisani, F.; Bernardi, G.; Calabresi, P. Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia. Stroke 2006, 37, 1319-1326.
122. Dodgson, S.J.; Shank, R.P.; Maryanoff, B.E. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 2000, 41, 35-39.
123. Kudin, A.P.; Debska-Vielhaber, G.; Vielhaber, S.; Elger, C.E.; Kunz, W.S. The mechanism of neuroprotection by topiramate in an animal model of epilepsy. Epilepsia 2004, 45, 1478-1487.
124. Ozyener, F.; Cetinkaya, M.; Alkan, T.; Goren, B.; Kafa, I.M.; Kurt, M.A.; Koksal, N. Neuroprotective effects of melatonin administered alone or in combination with topiramate in neonatal hypoxic-ischemic rat model. Restor. Neurol. Neurosci. 2012, 30, 435-444.
125. Noh, M.R.; Kim, S.K.; Sun, W.; Park, S.K.; Choi, H.C.; Lim, J.H.; Kim, I.H.; Kim, H.J.; Kim, H.; Eun, B.L. Neuroprotective effect of topiramate on hypoxic ischemic brain injury in neonatal rats. Exp. Neurol. 2006, 201, 470-478.
126. Galinsky, R.; Bennet, L.; Groenendaal, F.; Lear, C.A.; Tan, S.; van Bel, F.; Juul, S.E.; Robertson, N.J.; Mallard, C.; Gunn, A.J. Magnesium is not consistently neuroprotective for perinatal hypoxia-ischemia in term-equivalent models in preclinical studies: A systematic review. Dev. Neurosci. 2014, 36, 73-82.
127. Tagin, M.; Shah, P.S.; Lee, K.S. Magnesium for newborns with hypoxic-ischemic encephalopathy: A systematic review and meta-analysis. J. Perinatol. 2013, 33, 663-669.
128. Diamandis, T.; Borlongan, C.V. One, two, three steps toward cell therapy for stroke. Stroke 2015, 46, 588-591.
129. Rodriguez-Gomez, J.A.; Lu, J.Q.; Velasco, I.; Rivera, S.; Zoghbi, S.S.; Liow, J.S.; Musachio, J.L.; Chin, F.T.; Toyama, H.; Seidel, J. et al. Persistent dopamine functions of neurons derived from embryonic stem cells in a rodent model of parkinson disease. Stem Cells 2007, 25, 918-928.
130. Dimos, J.T.; Rodolfa, K.T.; Niakan, K.K.; Weisenthal, L.M.; Mitsumoto, H.; Chung, W.; Croft, G.F.; Saphier, G.; Leibel, R.; Goland, R. et al. Induced pluripotent stem cells generated from patients with als can be differentiated into motor neurons. Science 2008, 321, 1218-1221.
131. Roy, N.S.; Cleren, C.; Singh, S.K.; Yang, L.; Beal, M.F.; Goldman, S.A. Functional engraftment of human es cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat. Med. 2006, 12, 1259-1268.
132. Bliss, T.; Guzman, R.; Daadi, M.; Steinberg, G.K. Cell transplantation therapy for stroke. Stroke 2007, 38, 817-826.
133. Liao, Y.; Cotten, M.; Tan, S.; Kurtzberg, J.; Cairo, M.S. Rescuing the neonatal brain from hypoxic injury with autologous cord blood. Bone Marrow Transplant. 2013, 48, 890-900.
134. Denhardt, D.T.; Noda, M.; O'Regan, A.W.; Pavlin, D.; Berman, J.S. Osteopontin as a means to cope with environmental insults: Regulation of inflammation, tissue remodeling, and cell survival. J. Clin. Investig. 2001, 107, 1055-1061.
135. Mazzali, M.; Kipari, T.; Ophascharoensuk, V.; Wesson, J.A.; Johnson, R.; Hughes, J. Osteopontin-a molecule for all seasons. QJM: Int. J. Med. 2002, 95, 3-13
136. van Velthoven, C.T.; Heijnen, C.J.; van Bel, F.; Kavelaars, A. Osteopontin enhances endogenous repair after neonatal hypoxic-ischemic brain injury. Stroke 2011, 42, 2294-2301.
137. Chen, W.; Ma, Q.; Suzuki, H.; Hartman, R.; Tang, J.; Zhang, J.H. Osteopontin reduced hypoxia-ischemia neonatal brain injury by suppression of apoptosis in a rat pup model. Stroke 2011, 42, 764-769.
138. Bonestroo, H.J.; Nijboer, C.H.; van Velthoven, C.T.; van Bel, F.; Heijnen, C.J. The neonatal brain is not protected by osteopontin peptide treatment after hypoxia-ischemia. Dev. Neurosci. 2015, 37, 142-152.
139. Veldhuis, W.B.; Floris, S.; van der Meide, P.H.; Vos, I.M.; de Vries, H.E.; Dijkstra, C.D.; Bar, P.R.; Nicolay, K. Interferon-beta prevents cytokine-induced neutrophil infiltration and attenuates blood-brain barrier disruption. J. Cereb. Blood Flow Metab. 2003, 23, 1060-1069.
140. Maier, C.M.; Yu, F.; Nishi, T.; Lathrop, S.J.; Chan, P.H. Interferon-beta fails to protect in a model of transient focal stroke. Stroke 2006, 37, 1116-1119.
141. Bogoyevitch, M.A.; Boehm, I.; Oakley, A.; Ketterman, A.J.; Barr, R.K. Targeting the jnk mapk cascade for inhibition: Basic science and therapeutic potential. Biochim. Biophys. Acta Prot. Proteom. 2004, 1697, 89-101.
142. Karin, M.; Gallagher, E. From jnk to pay dirt: Jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life 2005, 57, 283-295.
143. Nijboer, C.H.; van der Kooij, M.A.; van Bel, F.; Ohl, F.; Heijnen, C.J.; Kavelaars, A. Inhibition of the jnk/ap-1 pathway reduces neuronal death and improves behavioral outcome after neonatal hypoxic-ischemic brain injury. Brain Behav. Immun. 2010, 24, 812-821.
144. Kaandorp, J.J.; van den Broek, M.P.; Benders, M.J.; Oudijk, M.A.; Porath, M.M.; Bambang Oetomo, S.; Wouters, M.G.; van Elburg, R.; Franssen, M.T.; Bos, A.F.; et al. Rapid target allopurinol concentrations in the hypoxic fetus after maternal administration during labour. Arch. Dis. Child. Fetal Aneonatal Ed. 2014, 99, 144-148.
145. Merchant, N.M.; Azzopardi, D.V.; Hawwa, A.F.; McElnay, J.C.; Middleton, B.; Arendt, J.; Arichi, T.; Gressens, P.; Edwards, A.D. Pharmacokinetics of melatonin in preterm infants. Br. J. Clin. Pharmacol. 2013, 76, 725-733.
146. Shea, K.L.; Palanisamy, A. What can you do to protect the newborn brain? Curr. Opin. Anaesthesiol. 2015, 28, 261-266.
147. Noor, J.I.; Ikeda, T.; Mishima, K.; Aoo, N.; Ohta, S.; Egashira, N.; Iwasaki, K.; Fujiwara, M.; Ikenoue, T. Short-term administration of a new free radical scavenger, edaravone, is more effective than its long-term administration for the treatment of neonatal hypoxic-ischemic encephalopathy. Stroke 2005, 36, 2468-2474.
148. Juul, S.E.; Yachnis, A.T.; Rojiani, A.M.; Christensen, R.D. Immunohistochemical localization of erythropoietin and its receptor in the developing human brain. Pediatr. Dev. Pathol. 1999, 2, 148-158.
149. Juul, S.E.; McPherson, R.J.; Farrell, F.X.; Jolliffe, L.; Ness, D.J.; Gleason, C.A. Erytropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin. Neonatology 2004, 85, 138-144.
150. Zhu, C.; Kang, W.; Xu, F.; Cheng, X.; Zhang, Z.; Jia, L.; Ji, L.; Guo, X.; Xiong, H.; Simbruner, G.; et al. Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics 2009, 124, 218-226.
151. Plateel, M.; Teissier, E.; Cecchelli, R. Hypoxia dramatically increases the nonspecific transport of blood-borne proteins to the brain. J. Neurochem. 1997, 68, 874-877.
152. Statler, P.A.; McPherson, R.J.; Bauer, L.A.; Kellert, B.A.; Juul, S.E. Pharmacokinetics of high-dose recombinant erythropoietin in plasma and brain of neonatal rats. Pediatr. Res. 2007, 61, 671-675.
153. Xenocostas, A.; Cheung, W.K.; Farrell, F.; Zakszewski, C.; Kelley, M.; Lutynski, A.; Crump, M.; Lipton, J.H.; Kiss, T.L.; Lau, C.Y. et al. The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin. Eur J. Clin. Pharmacol. 2005, 61, 189-195.
154. Wu, Y.W.; Bauer, L.A.; Ballard, R.A.; Ferriero, D.M.; Glidden, D.V.; Mayock, D.E.; Chang, T.; Durand, D.J.; Song, D.; Bonifacio, S.L. et al. Erythropoietin for neuroprotection in neonatal encephalopathy: Safety and pharmacokinetics. Pediatrics 2012, 130, 683-691.
155. Kumral, A.; Uysal, N.; Tugyan, K.; Sonmez, A.; Yilmaz, O.; Gokmen, N.; Kiray, M.; Genc, S.; Duman, N.; Koroglu, T.F. et al. Erythropoietin improves long-term spatial memory deficits and brain injury following neonatal hypoxia-ischemia in rats. Behav. Brain Res. 2004, 153, 77-86.
156. Gonzalez, F.F.; Abel, R.; Almli, C.R.; Mu, D.; Wendland, M.; Ferriero, D.M. Erythropoietin sustains cognitive function and brain volume after neonatal stroke. Dev. Neurosci. 2009, 31, 403-411.
157. Rogers, E.E.; Bonifacio, S.L.; Glass, H.C.; Juul, S.E.; Chang, T.; Mayock, D.E.; Durand, D.J.; Song, D.; Barkovich, A.J.; Ballard, R.A. et al. Erythropoietin and hypothermia for hypoxic-ischemic encephalopathy. Pediatr. Neurol. 2014, 51, 657-662.
158. Shankaran, S. Outcomes of hypoxic-ischemic encephalopathy in neonates treated with hypothermia. Clin. Perinatol. 2014, 41, 149-159.
159. Elmahdy, H.; El-Mashad, A.R.; El-Bahrawy, H.; El-Gohary, T.; El-Barbary, A.; Aly, H. Human recombinant erythropoietin in asphyxia neonatorum: Pilot trial. Pediatrics 2010, 125, 1135-1142.
160. Yin, D.; Kawabata, H.; Tcherniamtchouk, O.; Huynh, T.; Black, K.L.; Koeffler, H.P. Glioblastoma multiforme cells: Expression of erythropoietin receptor and response to erythropoietin. Int. J. Oncol. 2007, 31, 1193-1198.
161. Digicaylioglu, M.; Lipton, S.A. Erythropoietin-mediated neuroprotection involves cross-talk between jak2 and nf-kappab signalling cascades. Nature 2001, 412, 641-647.
162. Lee, S.T.; Chu, K.; Sinn, D.I.; Jung, K.H.; Kim, E.H.; Kim, S.J.; Kim, J.M.; Ko, S.Y.; Kim, M.; Roh, J.K. Erythropoietin reduces perihematomal inflammation and cell death with enos and stat3 activations in experimental intracerebral hemorrhage. J. Neurochem. 2006, 96, 1728-1739.
163. Park, M.H.; Lee, S.M.; Lee, J.W.; Son, D.J.; Moon, D.C.; Yoon, D.Y.; Hong, J.T. Erk-mediated production of neurotrophic factors by astrocytes promotes neuronal stem cell differentiation by erythropoietin. Biochem. Biophys. Res. Commun. 2006, 339, 1021-1028.
164. Peeters-Scholte, C.; Braun, K.; Koster, J.; Kops, N.; Blomgren, K.; Buonocore, G.; van Buul-Offers, S.; Hagberg, H.; Nicolay, K.; van Bel, F.; et al. Effects of allopurinol and deferoxamine on reperfusion injury of the brain in newborn piglets after neonatal hypoxia-ischemia. Pediatr. Res. 2003, 54, 516-522.
165. Benders, M.J.; Bos, A.F.; Rademaker, C.M.; Rijken, M.; Torrance, H.L.; Groenendaal, F.; van Bel, F. Early postnatal allopurinol does not improve short term outcome after severe birth asphyxia. Arch. Dis. Child. Fetal Neonatal Ed. 2006, 91, 163-165.
166. Kaandorp, J.J.; van Bel, F.; Veen, S.; Derks, J.B.; Groenendaal, F.; Rijken, M.; Roze, E.; Venema, M.M.; Rademaker, C.M.; Bos, A.F. et al. Long-term neuroprotective effects of allopurinol after moderate perinatal asphyxia: Follow-up of two randomised controlled trials. Arch. Dis. Child. Fetal Neonatal Ed. 2012, 97, 162-166.
167. Dworschak, M. Pharmacologic neuroprotection-is xenon the light at the end of the tunnel? Crit. Care Med. 2008, 36, 2477-2479.
168. Istaphanous, G.K.; Loepke, A.W. General anesthetics and the developing brain. Curr. Opin. Anaesthesiol. 2009, 22, 368-373.
169. Hobbs, C.; Thoresen, M.; Tucker, A.; Aquilina, K.; Chakkarapani, E.; Dingley, J. Xenon and hypothermia combine additively, offering long-term functional and histopathologic neuroprotection after neonatal hypoxia/ischemia. Stroke 2008, 39, 1307-1313.
170. Thoresen, M.; Hobbs, C.E.; Wood, T.; Chakkarapani, E.; Dingley, J. Cooling combined with immediate or delayed xenon inhalation provides equivalent long-term neuroprotection after neonatal hypoxia-ischemia. J. Cereb. Blood Flow Metab. 2009, 29, 707-714.
171. Dingley, J.; Tooley, J.; Liu, X.; Scull-Brown, E.; Elstad, M.; Chakkarapani, E.; Sabir, H.; Thoresen, M. Xenon ventilation during therapeutic hypothermia in neonatal encephalopathy: A feasibility study. Pediatrics 2014, 133, 809-818.
172. Robertson, N.J.; Tan, S.; Groenendaal, F.; van Bel, F.; Juul, S.E.; Bennet, L.; Derrick, M.; Back, S.A.; Valdez, R.C.; Northington, F., et al. Which neuroprotective agents are ready for bench to bedside translation in the newborn infant? J. Pediatr. 2012, 160, 544-552.
173. Cilio, M.R.; Ferriero, D.M. Synergistic neuroprotective therapies with hypothermia. Semin. Fetal Neonatal Med. 2010, 15, 293-298.
174. Guerrini, R.; Parmeggiani, L. Topiramate and its clinical applications in epilepsy. Expert Opin. Pharmacother. 2006, 7, 811-823.
175. Shank, R.P.; Gardocki, J.F.; Streeter, A.J.; Maryanoff, B.E. An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000, 41, 3-9.
176. Angehagen, M.; Ronnback, L.; Hansson, E.; Ben-Menachem, E. Topiramate reduces ampa-induced Ca2+ transients and inhibits glur1 subunit phosphorylation in astrocytes from primary cultures. J. Neurochem. 2005, 94, 1124-1130.
177. Sfaello, I.; Baud, O.; Arzimanoglou, A.; Gressens, P. Topiramate prevents excitotoxic damage in the newborn rodent brain. Neurobiol. Dis. 2005, 20, 837-848.
178. Zeevalk, G.D.; Nicklas, W.J. Evidence that the loss of the voltage-dependent Mg2+ block at the n-methyl-d-aspartate receptor underlies receptor activation during inhibition of neuronal metabolism. J. Neurochem. 1992, 59, 1211-1220.
179. Sugimoto, J.; Romani, A.M.; Valentin-Torres, A.M.; Luciano, A.A.; Ramirez Kitchen, C.M.; Funderburg, N.; Mesiano, S.; Bernstein, H.B. Magnesium decreases inflammatory cytokine production: A novel innate immunomodulatory mechanism. J. Immunol. 2012, 188, 6338-6346.
180. Hoffman, D.J.; Marro, P.J.; McGowan, J.E.; Mishra, O.P.; Delivoria-Papadopoulos, M. Protective effect of mgso4 infusion on nmda receptor binding characteristics during cerebral cortical hypoxia in the newborn piglet. Brain Res. 1994, 644, 144-149.
181. Shokry, M.; Elsedfy, G.O.; Bassiouny, M.M.; Anmin, M.; Abozid, H. Effects of antenatal magnesium sulfate therapy on cerebral and systemic hemodynamics in preterm newborns. Acta Obstet. Gynecol. Scand. 2010, 89, 801-806
182. de Haan, H.H.; Gunn, A.J.; Williams, C.E.; Heymann, M.A.; Gluckman, P.D. Magnesium sulfate therapy during asphyxia in near-term fetal lambs does not compromise the fetus but does not reduce cerebral injury. Am. J. Obstet. Gynecol. 1997, 176, 18-27.
183. Penrice, J.; Amess, P.N.; Punwani, S.; Wylezinska, M.; Tyszczuk, L.; D'Souza, P.; Edwards, A.D.; Cady, E.B.; Wyatt, J.S.; Reynolds, E.O. Magnesium sulfate after transient hypoxia-ischemia fails to prevent delayed cerebral energy failure in the newborn piglet. Pediatr. Res. 1997, 41, 443-447.
184. Greenwood, K.; Cox, P.; Mehmet, H.; Penrice, J.; Amess, P.N.; Cady, E.B.; Wyatt, J.S.; Edwards, A.D. Magnesium sulfate treatment after transient hypoxia-ischemia in the newborn piglet does not protect against cerebral damage. Pediatr. Res. 2000, 48, 346-350.
185. Schira, J.; Gasis, M.; Estrada, V.; Hendricks, M.; Schmitz, C.; Trapp, T.; Kruse, F.; Kogler, G.; Wernet, P.; Hartung, H.P.; et al. Significant clinical, neuropathological and behavioural recovery from acute spinal cord trauma by transplantation of a well-defined somatic stem cell from human umbilical cord blood. Brain 2012, 135, 431-446.
186. Escolar, M.L.; Poe, M.D.; Provenzale, J.M.; Richards, K.C.; Allison, J.; Wood, S.; Wenger, D.A.; Pietryga, D.; Wall, D.; Champagne, M. et al. Transplantation of umbilical-cord blood in babies with infantile krabbe's disease. N. Engl. J. Med. 2005, 352, 2069-2081.
187. Sun, J.; Allison, J.; McLaughlin, C.; Sledge, L.; Waters-Pick, B.; Wease, S.; Kurtzberg, J. Differences in quality between privately and publicly banked umbilical cord blood units: A pilot study of autologous cord blood infusion in children with acquired neurologic disorders. Transfusion 2010, 50, 1980-1987.
188. Cotten, C.M.; Murtha, A.P.; Goldberg, R.N.; Grotegut, C.A.; Smith, P.B.; Goldstein, R.F.; Fisher, K.A.; Gustafson, K.E.; Waters-Pick, B.; Swamy, G.K. et al. Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy. J. Pediatr. 2014, 164, 973-979.
189. Borlongan, C.V.; Weiss, M.D. Baby steps: A giant leap for cell therapy in neonatal brain injury. Pediatr. Res. 2011, 70, 3-9.
190. Gonzales-Portillo, G.S.; Reyes, S.; Aguirre, D.; Pabon, M.M.; Borlongan, C.V. Stem cell therapy for neonatal hypoxic-ischemic encephalopathy. Front. Neurol. 2014, 5, 147.
191. Katsuragi, S.; Ikeda, T.; Date, I.; Shingo, T.; Yasuhara, T.; Mishima, K.; Aoo, N.; Harada, K.; Egashira, N.; Iwasaki, K. et al. Implantation of encapsulated glial cell line-derived neurotrophic factor-secreting cells prevents long-lasting learning impairment following neonatal hypoxic-ischemic brain insult in rats. Am. J. Obstet. Gynecol. 2005, 192, 1028-1037.
192. Zalewska, T.; Jaworska, J.; Ziemka-Nalecz, M. Current and experimental pharmacological approaches in neonatal hypoxic-ischemic encephalopathy. Curr. Pharm. Des. 2015, 21, 1433-1439.
193. Douglas-Escobar, M.; Weiss, M.D. Biomarkers of hypoxic-ischemic encephalopathy in newborns. Front. Neurol. 2012, 3, 144.
194. Bennet, L.; Booth, L.; Gunn, A.J. Potential biomarkers for hypoxic-ischemic encephalopathy. Semin. Fetal Neonatal Med. 2010, 15, 253-260.
195. Meier, C.; Middelanis, J.; Wasielewski, B.; Neuhoff, S.; Roth-Haerer, A.; Gantert, M.; Dinse, H.R.; Dermietzel, R.; Jensen, A. Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells. Pediatr. Res. 2006, 59, 244-249.
196. Geissler, M.; Dinse, H.R.; Neuhoff, S.; Kreikemeier, K.; Meier, C. Human umbilical cord blood cells restore brain damage induced changes in rat somatosensory cortex. PLoS ONE 2011, 6, 20194.
197. Pimentel-Coelho, P.M.; Magalhães, E.S.; Lopes, L.M.; deAzevedo, L.C.; Santiago, M.F.; Mendez-Otero, R. Human cord blood transplantation in a neonatal rat model of hypoxic-ischemic brain damage: Functional outcome related to neuroprotection in the striatum. Stem Cells Dev. 2010, 19, 351-358.
198. Yasuhara, T.; Hara, K.; Maki, M.; Xu, L.; Yu, G.; Ali, M.M.; Masuda, T.; Yu, S.J.; Bae, E.K.; Hayashi, T. et al. Mannitol facilitates neurotrophic factor up-regulation and behavioural recovery in neonatal hypoxic-ischaemic rats with human umbilical cord blood grafts. J. Cell. Mol. Med. 2010, 14, 914-921.
199. De Paula, S.; Vitola, A.S.; Greggio, S.; de Paula, D.; Mello, P.B.; Lubianca, J.M.; Xavier, L.L.; Fiori, H.H.; Dacosta, J.C. Hemispheric brain injury and behavioral deficits induced by severe neonatal hypoxia-ischemia in rats are not attenuated by intravenous administration of human umbilical cord blood cells. Pediatr. Res. 2009, 65, 631-635.
200. Greggio, S.; de Paula, S.; Azevedo, P.N.; Venturin, G.T.; Dacosta, J.C. Intra-arterial transplantation of human umbilical cord blood mononuclear cells in neonatal hypoxic-ischemic rats. Life Sci. 2014, 96, 33-39.
201. Wang, X.; Zhao, Y.; Wang, X. Umbilical cord blood cells regulate the differentiation of endogenous neural stem cells in hypoxic ischemic neonatal rats via the hedgehog signaling pathway. Brain Res. 2014, 1560, 18-26.
202. Yasuhara, T.; Matsukawa, N.; Yu, G.; Xu, L.; Mays, R.W.; Kovach, J.; Deans, R.J.; Hess, D.C.; Carroll, J.E.; Borlongan, C.V. Behavioral and histological characterization of intrahippocampal grafts of human bone marrow-derived multipotent progenitor cells in neonatal rats with hypoxic-ischemic injury. Cell. Transplant. 2006, 15, 231-238.
203. Yasuhara, T.; Hara, K.; Maki, M.; Mays, R.W.; Deans, R.J.; Hess, D.C.; Carroll, J.E.; Borlongan, C.V. Intravenous grafts recapitulate the neurorestoration afforded by intracerebrally delivered multipotent adult progenitor cells in neonatal hypoxic-ischemic rats. J. Cereb. Blood Flow Metab. 2008, 28, 1804-1810.
204. Van Velthoven, C.T.J.; Kavelaars, A.; van Bel, F.; Heijnen, C.J. Repeated mesenchymal stem cell treatment after neonatal hypoxia-ischemia has distinct effects on formation and maturation of new neurons and oligodendrocytes leading to restoration of damage, corticospinal motor tract activity, and sensorimotor function. J. Neurosci. 2010, 30, 9603-9611.
205. Van Velthoven, C.T.J.; Kavelaars, A.; van Bel, F.; Heijnen, C.J. Nasal administration of stem cells: A promising novel route to treat neonatal ischemic brain damage. Pediatr. Res. 2010, 68, 419-422.
206. Donega, V.; Nijboer, C.H.; van Tilborg, G.; Dijkhuizen, R.M.; Kavelaars, A.; Heijnen, C.J. Intranasally administered mesenchymal stem cells promote a regenerative niche for repair of neonatal ischemic brain injury. Exp. Neurol. 2014, 261, 53-64.
207. Van Velthoven, C.T.; Braccioli, L.; Willemen, H.L.; Kavelaars, A.; Heijnen, C.J. Therapeutic potential of genetically modified mesenchymal stem cells after neonatal hypoxic-ischemic brain damage. Mol. Ther. 2014, 22, 645-654.
208. Liu, Y.; Jiang, X.; Zhang, X.; Chen, R.; Sun, T.; Fok, K.L.; Dong, J.; Tsang, L.L.; Yi, S.; Ruan, Y. et al. Dedifferentiation-reprogrammed mesenchymal stem cells with improved therapeutic potential. Stem Cells 2011, 29, 2077-2089.
209. Kim, E.S.; Ahn, S.Y.; Im, G.H.; Sung, D.K.; Park, Y.R.; Choi, S.H.; Choi, S.J.; Chang, Y.S.; Oh, W.; Lee, J.H. et al. Human umbilical cord blood-derived mesenchymal stem cell transplantation attenuates severe brain injury by permanent middle cerebral artery occlusion in newborn rats. Pediatr. Res. 2012, 72, 277-284.
210. Park, W.S.; Sung, S.I.; Ahn, S.Y.; Yoo, H.S.; Sung, D.K.; Im, G.H.; Choi, S.J.; Chang, Y.S. Hypothermia augments neuroprotective activity of mesenchymal stem cells for neonatal hypoxic-ischemic encephalopathy. PLoS ONE 2015, 10, 120893.
211. Xia, G.; Hong, X.; Chen, X.; Lan, F.; Zhang, G.; Liao, L. Intracerebral transplantation of mesenchymal stem cells derived from human umbilical cord blood alleviates hypoxic ischemic brain injury in rat neonates. J. Perinat. Med. 2010, 38, 215-221.
212. Zhang, X.; Zhang, Q.; Li, W.; Nie, D.; Chen, W.; Xu, C.; Yi, X.; Shi, J.; Tian, M.; Qin, J. et al. Therapeutic effect of human umbilical cord mesenchymal stem cells on neonatal rat hypoxic-ischemic encephalopathy. J. Neurosci. Res. 2014, 92, 35-45.
213. Lee, J.A.; Kim, B.I.; Jo, C.H.; Choi, C.W.; Kim, E.-K.; Kim, H.-S.; Yoon, K.-S.; Choi, J.-H. Mesenchymal stem-cell transplantation for hypoxic-ischemic brain injury in neonatal rat model. Pediatr. Res. 2010, 67, 42-46.
214. Yamagata, M.; Yamamoto, A.; Kako, E.; Kaneko, N.; Matsubara, K.; Sakai, K.; Sawamoto, K.; Ueda, M. Human dental pulp-derived stem cells protect against hypoxic-ischemic brain injury in neonatal mice. Stroke 2013, 44, 551-554.
215. Fang, C.; Yang, Y.; Wang, Q.; Yao, Y.; Zhang, X.; He, X. Intraventricular injection of human dental pulp stem cells improves hypoxic-ischemic brain damage in neonatal rats. PLoS ONE 2013, 8, 66748.
216. Park, K.I.; Teng, Y.D.; Snyder, E.Y. The injured brain interacts reciprocally with neural stem cells supported by scaffolds to reconstitute lost tissue. Nat. Biotechnol. 2002, 20, 1111-1117.
217. Park, K.I.; Himes, B.T.; Stieg, P.E.; Tessler, A.; Fischer, I.; Snyder, E.Y. Neural stem cells may be uniquely suited for combined gene therapy and cell replacement: Evidence from engraftment of Neurotrophin-3-expressing stem cells in hypoxic-ischemic brain injury. Exp. Neurol. 2006, 199, 179-190.
218. Daadi, M.M.; Davis, A.S.; Arac, A.; Li, Z.; Maag, A.-L.; Bhatnagar, R.; Jiang, K.; Sun, G.; Wu, J.C.; Steinberg, G.K. Human neural stem cell grafts modify microglial response and enhance axonal sprouting in neonatal hypoxic-ischemic brain injury. Stroke 2010, 41, 516-523.
219. Ashwal, S.; Ghosh, N.; Turenius, C.I.; Dulcich, M.; Denham, C.M.; Tone, B.; Hartman, R.; Snyder, E.Y.; Obenaus, A. Reparative effects of neural stem cells in neonatal rats with hypoxic-ischemic injury are not influenced by host sex. Pediatr. Res. 2014, 75, 603-611.
220. Chen, L.-X.; Ma, S.-M.; Zhang, P.; Fan, Z.-C.; Xiong, M.; Cheng, G.-Q.; Yang, Y.; Qiu, Z.-L.; Zhou, W.-H.; Li, J. Neuroprotective effects of oligodendrocyte progenitor cell transplantation in premature rat brain following hypoxic-ischemic injury. PLoS ONE 2015, 10, 115997.